Capricor Therapeutics (CAPR) Income towards Parent Company (2016 - 2025)
Historic Income towards Parent Company for Capricor Therapeutics (CAPR) over the last 17 years, with Q3 2025 value amounting to -$24.6 million.
- Capricor Therapeutics' Income towards Parent Company fell 9567.63% to -$24.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$57.5 million, marking a year-over-year decrease of 6825.08%. This contributed to the annual value of -$40.4 million for FY2024, which is 8059.67% down from last year.
- Capricor Therapeutics' Income towards Parent Company amounted to -$24.6 million in Q3 2025, which was down 9567.63% from -$25.9 million recorded in Q2 2025.
- Capricor Therapeutics' Income towards Parent Company's 5-year high stood at -$829093.0 during Q4 2023, with a 5-year trough of -$25.9 million in Q2 2025.
- In the last 5 years, Capricor Therapeutics' Income towards Parent Company had a median value of -$7.2 million in 2023 and averaged -$9.3 million.
- Per our database at Business Quant, Capricor Therapeutics' Income towards Parent Company soared by 8921.39% in 2023 and then tumbled by 74565.53% in 2024.
- Over the past 5 years, Capricor Therapeutics' Income towards Parent Company (Quarter) stood at -$6.4 million in 2021, then fell by 20.79% to -$7.7 million in 2022, then skyrocketed by 89.21% to -$829093.0 in 2023, then tumbled by 745.66% to -$7.0 million in 2024, then tumbled by 250.44% to -$24.6 million in 2025.
- Its Income towards Parent Company stands at -$24.6 million for Q3 2025, versus -$25.9 million for Q2 2025 and -$7.0 million for Q4 2024.